David A. Fruman

Title(s)Chair of Molecular Biology & Biochemistry, Molecular Biology & Biochemistry
SchoolSchool of Biological Sciences
Address3242 McGaugh Hall
Zot 3900
Irvine CA 92697
Phone(949) 824-1947, 2274
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Repurposing statins to enhance efficacy of BCL-2 antagonists in blood cancer
    NIH R21CA209341Jul 15, 2016 - Jun 30, 2019
    Role: Principal Investigator
    Regulation of B cell differentiation by eIF4E
    NIH R21AI124146Mar 16, 2016 - Feb 28, 2019
    Role: Principal Investigator
    Combination strategies to enhance therapy for Ph-like B-ALL
    NIH R21HD081319Mar 9, 2015 - Feb 28, 2018
    Role: Principal Investigator
    UCI-GPS: UC Irvine Graduate Professional Success
    NIH DP7OD020321Sep 18, 2014 - Feb 29, 2020
    Role: Principal Investigator
    Solving the elusive mechanism of rapamycin action in lymphocytes
    NIH R21AI099656Aug 20, 2012 - Jul 31, 2014
    Role: Principal Investigator
    TOR kinase inhibitors for leukemia therapy: mechanisms of action and resistance
    NIH R01CA158383Mar 12, 2012 - Feb 28, 2018
    Role: Principal Investigator
    Immunoregulatory effects of novel mTOR inhibitors
    NIH R03AI085462Feb 15, 2010 - Jan 31, 2012
    Role: Principal Investigator
    PI3K Signaling in Single Lymphocytes Analyzed by LMS
    NIH R21AI057900Apr 1, 2004 - Mar 31, 2007
    Role: Principal Investigator
    Phosphoinositide 3-Kinase Function in Lymphocytes
    NIH R01AI050831Jan 1, 2002 - Dec 31, 2007
    Role: Principal Investigator
    A Training Program for Interdisciplinary Cancer Research
    NIH T32CA009054Jul 1, 1980 - Jun 30, 2026
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer. Cancer Res. 2024 Jul 18. Hillis AL, Martin TD, Manchester HE, Högström J, Zhang N, Lecky E, Kozlova N, Lee J, Persky NS, Root DE, Brown M, Cichowski K, Elledge SJ, Muranen T, Fruman DA, Barry ST, Clohessy JG, Madsen RR, Toker A. PMID: 39024548.
      View in: PubMed   Mentions:
    2. The picky mTORC1 in metabolic enzyme degradation. Mol Cell. 2024 Jun 06; 84(11):2011-2013. Chun Y, Fruman DA, Lee G. PMID: 38848689.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    3. Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors. Cancer Res Commun. 2023 12 08; 3(12):2497-2509. Juarez D, Buono R, Matulis SM, Gupta VA, Duong M, Yudiono J, Paul M, Mallya S, Diep G, Hsin P, Lu A, Suh SM, Dong VM, Roberts AW, Leverson JD, Jalaluddin M, Liu Z, Bueno OF, Boise LH, Fruman DA. PMID: 37956312; PMCID: PMC10704957.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023 08 18; 22(1):138. Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, Kulke MH, Baird RD, Prabhu JS, Carbone D, Pecoraro C, Teh DBL, Sethi G, Cavalieri V, Lin KH, Javidi-Sharifi NR, Toska E, Davids MS, Brown JR, Diana P, Stebbing J, Fruman DA, Kumar AP. PMID: 37596643; PMCID: PMC10436543.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansCells
    5. The road less traveled: activating an oncogenic kinase. Trends Pharmacol Sci. 2023 10; 44(10):640-642. Paul M, Fruman DA. PMID: 37553270.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. The WW domain of IQGAP1 binds directly to the p110α catalytic subunit of PI 3-kinase. Biochem J. 2023 May 05. Bardwell AJ, Paul M, Yoneda KC, Andrade-Ludeña MD, Nguyen OT, Fruman D, Bardwell L. PMID: 37145016; PMCID: PMC10625650.
      View in: PubMed   Mentions:    Fields:    
    7. Synthesis of a Complex Brasilicardin Analogue Utilizing a Cobalt-Catalyzed MHAT-Induced Radical Bicyclization Reaction. Org Lett. 2023 05 19; 25(19):3451-3455. Niman SW, Buono R, Fruman DA, Vanderwal CD. PMID: 37141632; PMCID: PMC10204089.
      View in: PubMed   Mentions: 1     Fields:    Translation:Cells
    8. Novel pharmacological and dietary approaches to target mTOR in B-cell acute lymphoblastic leukemia. Front Oncol. 2023; 13:1162694. Buono R, Alhaddad M, Fruman DA. PMID: 37124486; PMCID: PMC10140551.
      View in: PubMed   Mentions: 1  
    9. Simultaneous inhibition of endocytic recycling and lysosomal fusion sensitizes cells and tissues to oligonucleotide therapeutics. Nucleic Acids Res. 2023 02 28; 51(4):1583-1599. Finicle BT, Eckenstein KH, Revenko AS, Anderson BA, Wan WB, McCracken AN, Gil D, Fruman DA, Hanessian S, Seth PP, Edinger AL. PMID: 36727438; PMCID: PMC9976930.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    10. Nanocomplexes of doxorubicin and DNA fragments for efficient and safe cancer chemotherapy. J Control Release. 2023 02; 354:91-108. Mohammad SN, Choi YS, Chung JY, Cedrone E, Neun BW, Dobrovolskaia MA, Yang X, Guo W, Chew YC, Kim J, Baek S, Kim IS, Fruman DA, Kwon YJ. PMID: 36572154.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    11. Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition. Sci Rep. 2021 11 04; 11(1):21689. Vo TT, Herzog LO, Buono R, Lee JS, Mallya S, Duong MR, Thao J, Gotesman M, Fruman DA. PMID: 34737376; PMCID: PMC8569117.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    12. Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia. Front Oncol. 2021; 11:673213. Lee BJ, Mallya S, Dinglasan N, Fung A, Nguyen T, Herzog LO, Thao J, Lorenzana EG, Wildes D, Singh M, Smith JAM, Fruman DA. PMID: 34408976; PMCID: PMC8366290.
      View in: PubMed   Mentions: 7  
    13. A cross-institutional analysis of the effects of broadening trainee professional development on research productivity. PLoS Biol. 2021 07; 19(7):e3000956. Brandt PD, Sturzenegger Varvayanis S, Baas T, Bolgioni AF, Alder J, Petrie KA, Dominguez I, Brown AM, Stayart CA, Singh H, Van Wart A, Chow CS, Mathur A, Schreiber BM, Fruman DA, Bowden B, Wiesen CA, Golightly YM, Holmquist CE, Arneman D, Hall JD, Hyman LE, Gould KL, Chalkley R, Brennwald PJ, Layton RL. PMID: 34264929; PMCID: PMC8282014.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    14. Reduced eIF4E function impairs B-cell leukemia without altering normal B-lymphocyte function. iScience. 2021 Jul 23; 24(7):102748. Chiu H, Buono R, Jackson LV, Herzog LO, Mallya S, Conn CS, Ruggero D, Fruman DA. PMID: 34278258; PMCID: PMC8261676.
      View in: PubMed   Mentions: 5  
    15. Targeting the Mevalonate Pathway in Cancer. Trends Cancer. 2021 06; 7(6):525-540. Juarez D, Fruman DA. PMID: 33358111; PMCID: PMC8137523.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    16. A Case for Phosphoinositide 3-Kinase-Targeted Therapy for Infectious Disease. J Immunol. 2020 12 15; 205(12):3237-3245. Adefemi F, Fruman DA, Marshall AJ. PMID: 33288538.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    17. Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax. Br J Cancer. 2021 03; 124(6):1098-1109. Herzog LO, Walters B, Buono R, Lee JS, Mallya S, Fung A, Chiu H, Nguyen N, Li B, Pinkerton AB, Jackson MR, Schneider RJ, Ronai ZA, Fruman DA. PMID: 33318657; PMCID: PMC7960756.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    18. YAP-mediated mechanotransduction tunes the macrophage inflammatory response. Sci Adv. 2020 12; 6(49). Meli VS, Atcha H, Veerasubramanian PK, Nagalla RR, Luu TU, Chen EY, Guerrero-Juarez CF, Yamaga K, Pandori W, Hsieh JY, Downing TL, Fruman DA, Lodoen MB, Plikus MV, Wang W, Liu WF. PMID: 33277245; PMCID: PMC7717914.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansCells
    19. Dietary glutamine supplementation suppresses epigenetically-activated oncogenic pathways to inhibit melanoma tumour growth. Nat Commun. 2020 07 03; 11(1):3326. Ishak Gabra MB, Yang Y, Li H, Senapati P, Hanse EA, Lowman XH, Tran TQ, Zhang L, Doan LT, Xu X, Schones DE, Fruman DA, Kong M. PMID: 32620791; PMCID: PMC7335172.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    20. An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia. Blood. 2020 06 25; 135(26):2337-2353. Ko TK, Javed A, Lee KL, Pathiraja TN, Liu X, Malik S, Soh SX, Heng XT, Takahashi N, Tan JHJ, Bhatia R, Khng AJ, Chng WJ, Sia YY, Fruman DA, Ng KP, Chan ZE, Xie KJ, Hoi Q, Chan CX, Teo ASM, Velazquez Camacho O, Meah WY, Khor CC, Ong CTJ, Soon WJW, Tan P, Ng PC, Chuah C, Hillmer AM, Ong ST. PMID: 32157296.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    21. Targeting PI3K-Gamma in Non-Hodgkin Lymphoma. J Clin Oncol. 2019 04 10; 37(11):932-934. Fruman DA. PMID: 30811291.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    22. The mTORC1/4E-BP/eIF4E Axis Promotes Antibody Class Switching in B Lymphocytes. J Immunol. 2019 01 15; 202(2):579-590. Chiu H, Jackson LV, Oh KI, Mai A, Ronai ZA, Ruggero D, Fruman DA. PMID: 30530594; PMCID: PMC6324996.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    23. Statins enhance efficacy of venetoclax in blood cancers. Sci Transl Med. 2018 06 13; 10(445). Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, Fleischman AG, O'Brien S, Lam LT, Leverson JD, Letai A, Schatz JH, Fruman DA. PMID: 29899021; PMCID: PMC6336198.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansAnimals
    24. Targeting the Mevalonate Pathway Suppresses VHL-Deficient CC-RCC through an HIF-Dependent Mechanism. Mol Cancer Ther. 2018 08; 17(8):1781-1792. Thompson JM, Alvarez A, Singha MK, Pavesic MW, Nguyen QH, Nelson LJ, Fruman DA, Razorenova OV. PMID: 29720560; PMCID: PMC6072609.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    25. The CD11a and Endothelial Protein C Receptor Marker Combination Simplifies and Improves the Purification of Mouse Hematopoietic Stem Cells. Stem Cells Transl Med. 2018 06; 7(6):468-476. Karimzadeh A, Scarfone VM, Varady E, Chao C, Grathwohl K, Fathman JW, Fruman DA, Serwold T, Inlay MA. PMID: 29543389; PMCID: PMC5980368.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    26. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. Oncotarget. 2018 Jan 30; 9(8):8027-8041. Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Cai T, Cavazos A, Tabe Y, Jacamo RO, Mu H, Zhao Y, Wang J, Wu SC, Cao F, Zeng Z, Zhou J, Mi Y, Jabbour EJ, Levine R, Tasian SK, Mullighan CG, Weinstock DM, Fruman DA, Konopleva M. PMID: 29487712; PMCID: PMC5814279.
      View in: PubMed   Mentions: 23     Fields:    
    27. mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL. Oncotarget. 2018 Jan 19; 9(5):6562-6571. Gotesman M, Vo TT, Herzog LO, Tea T, Mallya S, Tasian SK, Konopleva M, Fruman DA. PMID: 29464092; PMCID: PMC5814232.
      View in: PubMed   Mentions: 8     Fields:    
    28. The PI3K Pathway in Human Disease. Cell. 2017 Aug 10; 170(4):605-635. Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. PMID: 28802037; PMCID: PMC5726441.
      View in: PubMed   Mentions: 1016     Fields:    Translation:HumansAnimalsCells
    29. The Selective Phosphoinoside-3-Kinase p110δ Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation. Front Immunol. 2017; 8:747. Chiu H, Mallya S, Nguyen P, Mai A, Jackson LV, Winkler DG, DiNitto JP, Brophy EE, McGovern K, Kutok JL, Fruman DA. PMID: 28713374; PMCID: PMC5491903.
      View in: PubMed   Mentions: 9     Fields:    
    30. mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL. Mol Cancer Ther. 2017 09; 16(9):1942-1953. Vo TT, Lee JS, Nguyen D, Lui B, Pandori W, Khaw A, Mallya S, Lu M, Müschen M, Konopleva M, Fruman DA. PMID: 28566433; PMCID: PMC5619649.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    31. Cancer: A targeted treatment with off-target risks. Nature. 2017 02 23; 542(7642):424-425. Fruman DA, O'Brien S. PMID: 28199308.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    32. Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies. Blood. 2017 01 05; 129(1):88-99. Deng C, Lipstein MR, Scotto L, Jirau Serrano XO, Mangone MA, Li S, Vendome J, Hao Y, Xu X, Deng SX, Realubit RB, Tatonetti NP, Karan C, Lentzsch S, Fruman DA, Honig B, Landry DW, O'Connor OA. PMID: 27784673; PMCID: PMC5216267.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansAnimalsCells
    33. Context-Specific Function of S6K2 in Th Cell Differentiation. J Immunol. 2016 10 15; 197(8):3049-3058. Pai C, Walsh CM, Fruman DA. PMID: 27613697; PMCID: PMC5101169.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    34. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells. Oncotarget. 2016 Aug 23; 7(34):55083-55097. Zeng Z, Wang RY, Qiu YH, Mak DH, Coombes K, Yoo SY, Zhang Q, Jessen K, Liu Y, Rommel C, Fruman DA, Kantarjian HM, Kornblau SM, Andreeff M, Konopleva M. PMID: 27391151; PMCID: PMC5342403.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    35. Viral/Nonviral Chimeric Nanoparticles To Synergistically Suppress Leukemia Proliferation via Simultaneous Gene Transduction and Silencing. ACS Nano. 2016 09 27; 10(9):8705-14. Hong CA, Cho SK, Edson JA, Kim J, Ingato D, Pham B, Chuang A, Fruman DA, Kwon YJ. PMID: 27472284; PMCID: PMC5602606.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    36. mTOR signaling: new networks for ALL. Blood. 2016 06 02; 127(22):2658-9. Fruman DA. PMID: 27257176; PMCID: PMC4891950.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    37. The 4E-BP-eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes. Sci Signal. 2016 05 31; 9(430):ra57. So L, Lee J, Palafox M, Mallya S, Woxland CG, Arguello M, Truitt ML, Sonenberg N, Ruggero D, Fruman DA. PMID: 27245614; PMCID: PMC4924540.
      View in: PubMed   Mentions: 37     Fields:    Translation:AnimalsCells
    38. Targeting mTOR for the treatment of B cell malignancies. Br J Clin Pharmacol. 2016 11; 82(5):1213-1228. Lee JS, Vo TT, Fruman DA. PMID: 26805380; PMCID: PMC5061788.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    39. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. Oncotarget. 2015 Nov 03; 6(34):35202-17. Lee JS, Tang SS, Ortiz V, Vo TT, Fruman DA. PMID: 26460954; PMCID: PMC4742099.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    40. INPP4B Is a Tumor Suppressor in the Context of PTEN Deficiency. Cancer Discov. 2015 Jul; 5(7):697-700. Vo TT, Fruman DA. PMID: 26152921; PMCID: PMC4499858.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    41. mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells. Oncotarget. 2015 Feb 10; 6(4):2088-100. Beagle BR, Nguyen DM, Mallya S, Tang SS, Lu M, Zeng Z, Konopleva M, Vo TT, Fruman DA. PMID: 25576920; PMCID: PMC4385838.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    42. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proc Natl Acad Sci U S A. 2014 Nov 25; 111(47):E5076-85. Limon JJ, So L, Jellbauer S, Chiu H, Corado J, Sykes SM, Raffatellu M, Fruman DA. PMID: 25385646; PMCID: PMC4250172.
      View in: PubMed   Mentions: 43     Fields:    Translation:AnimalsCells
    43. Too much of a good thing: immunodeficiency due to hyperactive PI3K signaling. J Clin Invest. 2014 Sep; 124(9):3688-90. Walsh CM, Fruman DA. PMID: 25133419; PMCID: PMC4151232.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    44. Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function. PLoS One. 2014; 9(6):e99486. Yea SS, So L, Mallya S, Lee J, Rajasekaran K, Malarkannan S, Fruman DA. PMID: 24915189; PMCID: PMC4051752.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    45. DNA-scaffolded multivalent ligands to modulate cell function. Chembiochem. 2014 Jun 16; 15(9):1268-73. Zhang Z, Eckert MA, Ali MM, Liu L, Kang DK, Chang E, Pone EJ, Sender LS, Fruman DA, Zhao W. PMID: 24803415.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    46. Idelalisib--a PI3Kδ inhibitor for B-cell cancers. N Engl J Med. 2014 Mar 13; 370(11):1061-2. Fruman DA, Cantley LC. PMID: 24620870; PMCID: PMC4088325.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    47. Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1. PLoS One. 2014; 9(2):e88865. Mallya S, Fitch BA, Lee JS, So L, Janes MR, Fruman DA. PMID: 24586420; PMCID: PMC3931643.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    48. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014 Feb; 13(2):140-56. Fruman DA, Rommel C. PMID: 24481312; PMCID: PMC3994981.
      View in: PubMed   Mentions: 799     Fields:    Translation:HumansAnimalsCells
    49. Genetics. Can cancer drugs treat immunodeficiency? Science. 2013 Nov 15; 342(6160):814-5. Conley ME, Fruman DA. PMID: 24233715.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    50. A polyvalent aptamer system for targeted drug delivery. Biomaterials. 2013 Dec; 34(37):9728-35. Zhang Z, Ali MM, Eckert MA, Kang DK, Chen YY, Sender LS, Fruman DA, Zhao W. PMID: 24044994.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    51. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. Proc Natl Acad Sci U S A. 2013 Jun 18; 110(25):E2298-307. Lim S, Saw TY, Zhang M, Janes MR, Nacro K, Hill J, Lim AQ, Chang CT, Fruman DA, Rizzieri DA, Tan SY, Fan H, Chuah CT, Ong ST. PMID: 23737503; PMCID: PMC3690864.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansAnimalsCells
    52. Achieving cancer cell death with PI3K/mTOR-targeted therapies. Ann N Y Acad Sci. 2013 Mar; 1280:15-8. Yea SS, Fruman DA. PMID: 23551096; PMCID: PMC3621026.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    53. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function. J Biol Chem. 2013 Feb 22; 288(8):5718-31. So L, Yea SS, Oak JS, Lu M, Manmadhan A, Ke QH, Janes MR, Kessler LV, Kucharski JM, Li LS, Martin MB, Ren P, Jessen KA, Liu Y, Rommel C, Fruman DA. PMID: 23275335; PMCID: PMC3581375.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    54. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. 2013 Mar; 27(3):586-94. Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, Fruman DA. PMID: 23090679; PMCID: PMC3593948.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansAnimalsCells
    55. Akt and mTOR in B Cell Activation and Differentiation. Front Immunol. 2012; 3:228. Limon JJ, Fruman DA. PMID: 22888331; PMCID: PMC3412259.
      View in: PubMed   Mentions: 93     Fields:    
    56. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood. 2012 Sep 27; 120(13):2679-89. Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, Konopleva M. PMID: 22826565; PMCID: PMC3460689.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansAnimalsCells
    57. PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem J. 2012 Mar 15; 442(3):465-81. So L, Fruman DA. PMID: 22364281; PMCID: PMC3539736.
      View in: PubMed   Mentions: 98     Fields:    Translation:HumansAnimalsCells
    58. Link between inflammation and aquaporin-5 distribution in submandibular gland in Sjögren's syndrome? Oral Dis. 2012 Sep; 18(6):568-74. Soyfoo MS, Konno A, Bolaky N, Oak JS, Fruman D, Nicaise C, Takiguchi M, Delporte C. PMID: 22320885.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    59. The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia. Methods Mol Biol. 2012; 821:251-65. Janes MR, Fruman DA. PMID: 22125070.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    60. PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov. 2011 Dec; 1(7):562-72. Fruman DA, Rommel C. PMID: 22586681.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansAnimals
    61. Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins. Biochem J. 2011 Oct 15; 439(2):299-311. Romero Rosales K, Singh G, Wu K, Chen J, Janes MR, Lilly MB, Peralta ER, Siskind LJ, Bennett MJ, Fruman DA, Edinger AL. PMID: 21767261; PMCID: PMC3454501.
      View in: PubMed   Mentions: 29     Fields:    Translation:AnimalsCells
    62. A lipid kinase cousin cooperates to promote cancer. Cancer Cell. 2011 Jun 14; 19(6):693-5. Beagle B, Fruman DA. PMID: 21665142; PMCID: PMC3129267.
      View in: PubMed   Mentions: 9     Fields:    
    63. Cell signaling. New mTOR targets Grb attention. Science. 2011 Jun 10; 332(6035):1270-1. Yea SS, Fruman DA. PMID: 21659593.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    64. B-1 cell lymphoma in mice lacking the steroid and xenobiotic receptor, SXR. Mol Endocrinol. 2011 Jun; 25(6):933-43. Casey SC, Nelson EL, Turco GM, Janes MR, Fruman DA, Blumberg B. PMID: 21436254; PMCID: PMC3100607.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    65. Target of rapamycin signaling in leukemia and lymphoma. Clin Cancer Res. 2010 Nov 15; 16(22):5374-80. Vu C, Fruman DA. PMID: 20826559.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    66. B cell receptor signaling: picky about PI3Ks. Sci Signal. 2010 Aug 10; 3(134):pe25. Limon JJ, Fruman DA. PMID: 20699473.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    67. Foxo1 regulates marginal zone B-cell development. Eur J Immunol. 2010 Jul; 40(7):1890-6. Chen J, Limon JJ, Blanc C, Peng SL, Fruman DA. PMID: 20449867; PMCID: PMC2926184.
      View in: PubMed   Mentions: 23     Fields:    Translation:AnimalsCells
    68. Targeting TOR dependence in cancer. Oncotarget. 2010 May; 1(1):69-76. Janes MR, Fruman DA. PMID: 20657741; PMCID: PMC2908250.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    69. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med. 2010 Feb; 16(2):205-13. Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA. PMID: 20072130; PMCID: PMC4017764.
      View in: PubMed   Mentions: 190     Fields:    Translation:HumansAnimals
    70. Regulatory subunits of class IA PI3K. Curr Top Microbiol Immunol. 2010; 346:225-44. Fruman DA. PMID: 20563711.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    71. PI3Ks in lymphocyte signaling and development. Curr Top Microbiol Immunol. 2010; 346:57-85. Okkenhaug K, Fruman DA. PMID: 20563708; PMCID: PMC4499567.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimalsCells
    72. Organ-specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene-targeting of the PI3K regulatory isoforms p85alpha, p55alpha, and p50alpha. Dev Dyn. 2009 Oct; 238(10):2670-9. Mouta-Bellum C, Kirov A, Miceli-Libby L, Mancini ML, Petrova TV, Liaw L, Prudovsky I, Thorpe PE, Miura N, Cantley LC, Alitalo K, Fruman DA, Vary CP. PMID: 19705443; PMCID: PMC2826787.
      View in: PubMed   Mentions: 34     Fields:    Translation:AnimalsCells
    73. The p85beta regulatory subunit of phosphoinositide 3-kinase has unique and redundant functions in B cells. Autoimmunity. 2009 Aug; 42(5):447-58. Oak JS, Chen J, Peralta RQ, Deane JA, Fruman DA. PMID: 19811262; PMCID: PMC2804088.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    74. Immune regulation by rapamycin: moving beyond T cells. Sci Signal. 2009 Apr 21; 2(67):pe25. Janes MR, Fruman DA. PMID: 19383976.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    75. Fine tuning the immune response with PI3K. Immunol Rev. 2009 Mar; 228(1):253-72. Fruman DA, Bismuth G. PMID: 19290933.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansAnimalsCells
    76. p85beta phosphoinositide 3-kinase regulates CD28 coreceptor function. Blood. 2009 Apr 02; 113(14):3198-208. Alcázar I, Cortés I, Zaballos A, Hernandez C, Fruman DA, Barber DF, Carrera AC. PMID: 19190244; PMCID: PMC2945823.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    77. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest. 2008 Sep; 118(9):3038-50. Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA. PMID: 18704194; PMCID: PMC2515380.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansAnimalsCells
    78. FOXO1 regulates L-Selectin and a network of human T cell homing molecules downstream of phosphatidylinositol 3-kinase. J Immunol. 2008 Sep 01; 181(5):2980-9. Fabre S, Carrette F, Chen J, Lang V, Semichon M, Denoyelle C, Lazar V, Cagnard N, Dubart-Kupperschmitt A, Mangeney M, Fruman DA, Bismuth G. PMID: 18713968.
      View in: PubMed   Mentions: 109     Fields:    Translation:HumansCells
    79. Cancer therapy: staying current with AMPK. Biochem J. 2008 Jun 01; 412(2):e3-5. Fruman DA, Edinger AL. PMID: 18466113.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    80. T cell Ig and mucin domain-1-mediated T cell activation requires recruitment and activation of phosphoinositide 3-kinase. J Immunol. 2008 May 15; 180(10):6518-26. de Souza AJ, Oak JS, Jordanhazy R, DeKruyff RH, Fruman DA, Kane LP. PMID: 18453570; PMCID: PMC2637999.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansAnimalsCells
    81. KLF4 is a FOXO target gene that suppresses B cell proliferation. Int Immunol. 2008 May; 20(5):671-81. Yusuf I, Kharas MG, Chen J, Peralta RQ, Maruniak A, Sareen P, Yang VW, Kaestner KH, Fruman DA. PMID: 18375530.
      View in: PubMed   Mentions: 39     Fields:    Translation:AnimalsCells
    82. Lymphocyte cell motility: the twisting, turning tale of phosphoinositide 3-kinase. Biochem Soc Trans. 2007 Nov; 35(Pt 5):1109-13. Oak JS, Matheu MP, Parker I, Cahalan MD, Fruman DA. PMID: 17956290; PMCID: PMC2953540.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    83. Distinct signaling mechanisms activate the target of rapamycin in response to different B-cell stimuli. Eur J Immunol. 2007 Oct; 37(10):2923-36. Donahue AC, Fruman DA. PMID: 17724683.
      View in: PubMed   Mentions: 44     Fields:    Translation:AnimalsCells
    84. Role of phosphoinositide 3-kinase signaling in autoimmunity. Autoimmunity. 2007 Sep; 40(6):433-41. Oak JS, Fruman DA. PMID: 17729037.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    85. Signal transduction and autoimmunity: introduction. Autoimmunity. 2007 Sep; 40(6):403-4. Fruman DA, Walsh CM. PMID: 17729032.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    86. Class IA phosphoinositide 3-kinase modulates basal lymphocyte motility in the lymph node. J Immunol. 2007 Aug 15; 179(4):2261-9. Matheu MP, Deane JA, Parker I, Fruman DA, Cahalan MD. PMID: 17675487.
      View in: PubMed   Mentions: 21     Fields:    Translation:AnimalsCells
    87. T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling. Blood. 2007 Apr 01; 109(7):2894-902. Deane JA, Kharas MG, Oak JS, Stiles LN, Luo J, Moore TI, Ji H, Rommel C, Cantley LC, Lane TE, Fruman DA. PMID: 17164340; PMCID: PMC1852227.
      View in: PubMed   Mentions: 27     Fields:    Translation:AnimalsCells
    88. The role of class I phosphoinositide 3-kinase in T-cell function and autoimmunity. Biochem Soc Trans. 2007 Apr; 35(Pt 2):177-80. Fruman DA. PMID: 17371231.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    89. Measuring phosphorylated Akt and other phosphoinositide 3-kinase-regulated phosphoproteins in primary lymphocytes. Methods Enzymol. 2007; 434:131-54. Donahue AC, Kharas MG, Fruman DA. PMID: 17954246.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    90. Sjögren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase. Proc Natl Acad Sci U S A. 2006 Nov 07; 103(45):16882-7. Oak JS, Deane JA, Kharas MG, Luo J, Lane TE, Cantley LC, Fruman DA. PMID: 17071741; PMCID: PMC1636548.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    91. KLF4 suppresses transformation of pre-B cells by ABL oncogenes. Blood. 2007 Jan 15; 109(2):747-55. Kharas MG, Yusuf I, Scarfone VM, Yang VW, Segre JA, Huettner CS, Fruman DA. PMID: 16954505; PMCID: PMC1785099.
      View in: PubMed   Mentions: 41     Fields:    Translation:AnimalsCells
    92. FOXO transcription factors cooperate with delta EF1 to activate growth suppressive genes in B lymphocytes. J Immunol. 2006 Mar 01; 176(5):2711-21. Chen J, Yusuf I, Andersen HM, Fruman DA. PMID: 16493026.
      View in: PubMed   Mentions: 36     Fields:    Translation:AnimalsCells
    93. S6 kinase 2 potentiates interleukin-3-driven cell proliferation. J Leukoc Biol. 2005 Dec; 78(6):1378-85. Cruz R, Hedden L, Boyer D, Kharas MG, Fruman DA, Lee-Fruman KK. PMID: 16204634; PMCID: PMC2424256.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    94. Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement. Mol Cell Biol. 2005 Apr; 25(7):2593-606. Brachmann SM, Yballe CM, Innocenti M, Deane JA, Fruman DA, Thomas SM, Cantley LC. PMID: 15767666; PMCID: PMC1061637.
      View in: PubMed   Mentions: 63     Fields:    Translation:AnimalsCells
    95. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res. 2005 Mar 15; 65(6):2047-53. Kharas MG, Fruman DA. PMID: 15781610.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansAnimalsCells
    96. Analysis of the major patterns of B cell gene expression changes in response to short-term stimulation with 33 single ligands. J Immunol. 2004 Dec 15; 173(12):7141-9. Zhu X, Hart R, Chang MS, Kim JW, Lee SY, Cao YA, Mock D, Ke E, Saunders B, Alexander A, Grossoehme J, Lin KM, Yan Z, Hsueh R, Lee J, Scheuermann RH, Fruman DA, Seaman W, Subramaniam S, Sternweis P, Simon MI, Choi S. PMID: 15585835.
      View in: PubMed   Mentions: 34     Fields:    Translation:AnimalsCells
    97. Altered splenic B cell subset development in mice lacking phosphoinositide 3-kinase p85alpha. Int Immunol. 2004 Dec; 16(12):1789-98. Donahue AC, Hess KL, Ng KL, Fruman DA. PMID: 15520044.
      View in: PubMed   Mentions: 14     Fields:    Translation:AnimalsCells
    98. Frontline: The p85alpha isoform of phosphoinositide 3-kinase is essential for a subset of B cell receptor-initiated signaling responses. Eur J Immunol. 2004 Nov; 34(11):2968-76. Hess KL, Donahue AC, Ng KL, Moore TI, Oak J, Fruman DA. PMID: 15384044.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    99. Phosphoinositide 3-kinase and its targets in B-cell and T-cell signaling. Curr Opin Immunol. 2004 Jun; 16(3):314-20. Fruman DA. PMID: 15134780.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansAnimalsCells
    100. Enhanced T cell proliferation in mice lacking the p85beta subunit of phosphoinositide 3-kinase. J Immunol. 2004 Jun 01; 172(11):6615-25. Deane JA, Trifilo MJ, Yballe CM, Choi S, Lane TE, Fruman DA. PMID: 15153476.
      View in: PubMed   Mentions: 32     Fields:    Translation:AnimalsCells
    101. Optimal B-cell proliferation requires phosphoinositide 3-kinase-dependent inactivation of FOXO transcription factors. Blood. 2004 Aug 01; 104(3):784-7. Yusuf I, Zhu X, Kharas MG, Chen J, Fruman DA. PMID: 15069012.
      View in: PubMed   Mentions: 63     Fields:    Translation:AnimalsCells
    102. PI3K signaling controls cell fate at many points in B lymphocyte development and activation. Semin Cell Dev Biol. 2004 Apr; 15(2):183-97. Donahue AC, Fruman DA. PMID: 15209378.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    103. Towards an understanding of isoform specificity in phosphoinositide 3-kinase signalling in lymphocytes. Biochem Soc Trans. 2004 Apr; 32(Pt 2):315-9. Fruman DA. PMID: 15046598.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    104. Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood. 2004 Jun 01; 103(11):4268-75. Kharas MG, Deane JA, Wong S, O'Bosky KR, Rosenberg N, Witte ON, Fruman DA. PMID: 14976048.
      View in: PubMed   Mentions: 35     Fields:    Translation:AnimalsCells
    105. Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu Rev Immunol. 2004; 22:563-98. Deane JA, Fruman DA. PMID: 15032589.
      View in: PubMed   Mentions: 119     Fields:    Translation:HumansAnimalsCells
    106. Transformation of mouse fibroblasts by Jaagsiekte sheep retrovirus envelope does not require phosphatidylinositol 3-kinase. J Virol. 2003 Sep; 77(18):9951-9. Maeda N, Inoshima Y, Fruman DA, Brachmann SM, Fan H. PMID: 12941905; PMCID: PMC224593.
      View in: PubMed   Mentions: 23     Fields:    Translation:AnimalsCells
    107. Regulation of quiescence in lymphocytes. Trends Immunol. 2003 Jul; 24(7):380-6. Yusuf I, Fruman DA. PMID: 12860529.
      View in: PubMed   Mentions: 89     Fields:    Translation:HumansAnimalsCells
    108. Proliferation and survival of activated B cells requires sustained antigen receptor engagement and phosphoinositide 3-kinase activation. J Immunol. 2003 Jun 15; 170(12):5851-60. Donahue AC, Fruman DA. PMID: 12794110.
      View in: PubMed   Mentions: 32     Fields:    Translation:AnimalsCells
    109. Overview of the Alliance for Cellular Signaling. Nature. 2002 Dec 12; 420(6916):703-6. Gilman AG, Simon MI, Bourne HR, Harris BA, Long R, Ross EM, Stull JT, Taussig R, Bourne HR, Arkin AP, Cobb MH, Cyster JG, Devreotes PN, Ferrell JE, Fruman D, Gold M, Weiss A, Stull JT, Berridge MJ, Cantley LC, Catterall WA, Coughlin SR, Olson EN, Smith TF, Brugge JS, Botstein D, Dixon JE, Hunter T, Lefkowitz RJ, Pawson AJ, Sternberg PW, Varmus H, Subramaniam S, Sinkovits RS, Li J, Mock D, Ning Y, Saunders B, Sternweis PC, Hilgemann D, Scheuermann RH, DeCamp D, Hsueh R, Lin KM, Ni Y, Seaman WE, Simpson PC, O'Connell TD, Roach T, Simon MI, Choi S, Eversole-Cire P, Fraser I, Mumby MC, Zhao Y, Brekken D, Shu H, Meyer T, Chandy G, Heo WD, Liou J, O'Rourke N, Verghese M, Mumby SM, Han H, Brown HA, Forrester JS, Ivanova P, Milne SB, Casey PJ, Harden TK, Arkin AP, Doyle J, Gray ML, Meyer T, Michnick S, Schmidt MA, Toner M, Tsien RY, Natarajan M, Ranganathan R, Sambrano GR, Participating investigators and scientists of the Alliance for Cellular Signaling. PMID: 12478301.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    110. Altered signaling and cell cycle regulation in embryonal stem cells with a disruption of the gene for phosphoinositide 3-kinase regulatory subunit p85alpha. J Biol Chem. 2003 Feb 14; 278(7):5099-108. Hallmann D, Trümper K, Trusheim H, Ueki K, Kahn CR, Cantley LC, Fruman DA, Hörsch D. PMID: 12435753; PMCID: PMC3205087.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    111. Phosphoinositide 3-kinase in immunological systems. Semin Immunol. 2002 Feb; 14(1):7-18. Fruman DA, Cantley LC. PMID: 11884226.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansAnimalsCells
    112. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol. 2002 Feb; 22(3):965-77. Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR. PMID: 11784871; PMCID: PMC133541.
      View in: PubMed   Mentions: 103     Fields:    Translation:AnimalsCells
    113. Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest. 2002 Jan; 109(1):141-9. Mauvais-Jarvis F, Ueki K, Fruman DA, Hirshman MF, Sakamoto K, Goodyear LJ, Iannacone M, Accili D, Cantley LC, Kahn CR. PMID: 11781359; PMCID: PMC150818.
      View in: PubMed   Mentions: 100     Fields:    Translation:AnimalsCells
    114. Phosphoinositide 3-kinase and Bruton's tyrosine kinase regulate overlapping sets of genes in B lymphocytes. Proc Natl Acad Sci U S A. 2002 Jan 08; 99(1):359-64. Fruman DA, Ferl GZ, An SS, Donahue AC, Satterthwaite AB, Witte ON. PMID: 11756681; PMCID: PMC117565.
      View in: PubMed   Mentions: 23     Fields:    Translation:AnimalsCells
    115. Phosphatidylinositol 3-kinase confers resistance to encephalomyocarditis and herpes simplex virus-induced cell death through the activation of distinct downstream effectors. J Immunol. 2001 Oct 15; 167(8):4553-9. Prejean C, Sarma T, Kurnasov O, Usacheva A, Hemmings B, Cantley L, Fruman DA, Morrison LA, Buller RM, Colamonici OR. PMID: 11591783.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    116. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha. Nat Genet. 2000 Nov; 26(3):379-82. Fruman DA, Mauvais-Jarvis F, Pollard DA, Yballe CM, Brazil D, Bronson RT, Kahn CR, Cantley LC. PMID: 11062485.
      View in: PubMed   Mentions: 96     Fields:    Translation:AnimalsCells
    117. A peptide library approach identifies a specific inhibitor for the ZAP-70 protein tyrosine kinase. Mol Cell. 2000 Oct; 6(4):969-74. Nishikawa K, Sawasdikosol S, Fruman DA, Lai J, Songyang Z, Burakoff SJ, Yaffe MB, Cantley LC. PMID: 11090635.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    118. Xid-like phenotypes: a B cell signalosome takes shape. Immunity. 2000 Jul; 13(1):1-3. Fruman DA, Satterthwaite AB, Witte ON. PMID: 10933389.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansAnimalsCells
    119. A sensitized genetic system for the analysis of murine B lymphocyte signal transduction pathways dependent on Bruton's tyrosine kinase. Proc Natl Acad Sci U S A. 2000 Jun 06; 97(12):6687-92. Satterthwaite AB, Willis F, Kanchanastit P, Fruman D, Cantley LC, Helgason CD, Humphries RK, Lowell CA, Simon M, Leitges M, Tarakhovsky A, Tedder TF, Lesche R, Wu H, Witte ON. PMID: 10829070; PMCID: PMC18703.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    120. Impaired kit- but not FcepsilonRI-initiated mast cell activation in the absence of phosphoinositide 3-kinase p85alpha gene products. J Biol Chem. 2000 Feb 25; 275(8):6022-9. Lu-Kuo JM, Fruman DA, Joyal DM, Cantley LC, Katz HR. PMID: 10681597.
      View in: PubMed   Mentions: 18     Fields:    Translation:AnimalsCells
    121. SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling. J Biol Chem. 1999 Nov 12; 274(46):32662-6. Beitz LO, Fruman DA, Kurosaki T, Cantley LC, Scharenberg AM. PMID: 10551821.
      View in: PubMed   Mentions: 58     Fields:    Translation:AnimalsCells
    122. Mouse phosphoinositide 3-kinase p110alpha gene: cloning, structural organization, and localization to chromosome 3 band B. Biochem Biophys Res Commun. 1999 Aug 27; 262(2):438-42. Aksoy IA, Ramsey MJ, Fruman DA, Aksoy S, Cantley LC, Tucker JD, Roberts TM. PMID: 10462494.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    123. Phosphoinositide 3-kinase knockout mice: role of p85alpha in B cell development and proliferation. Biochem Soc Trans. 1999 Aug; 27(4):624-9. Fruman DA, Snapper SB, Yballe CM, Alt FW, Cantley LC. PMID: 10917654.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    124. Phosphoinositide binding domains: embracing 3-phosphate. Cell. 1999 Jun 25; 97(7):817-20. Fruman DA, Rameh LE, Cantley LC. PMID: 10399908.
      View in: PubMed   Mentions: 26     Fields:    Translation:AnimalsCells
    125. The SH2 domain-containing inositol 5'-phosphatase (SHIP) recruits the p85 subunit of phosphoinositide 3-kinase during FcgammaRIIb1-mediated inhibition of B cell receptor signaling. J Biol Chem. 1999 Mar 12; 274(11):7489-94. Gupta N, Scharenberg AM, Fruman DA, Cantley LC, Kinet JP, Long EO. PMID: 10066815.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    126. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science. 1999 Jan 15; 283(5400):393-7. Fruman DA, Snapper SB, Yballe CM, Davidson L, Yu JY, Alt FW, Cantley LC. PMID: 9888855.
      View in: PubMed   Mentions: 177     Fields:    Translation:AnimalsCells
    127. Phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3)/Tec kinase-dependent calcium signaling pathway: a target for SHIP-mediated inhibitory signals. EMBO J. 1998 Apr 01; 17(7):1961-72. Scharenberg AM, El-Hillal O, Fruman DA, Beitz LO, Li Z, Lin S, Gout I, Cantley LC, Rawlings DJ, Kinet JP. PMID: 9524119; PMCID: PMC1170542.
      View in: PubMed   Mentions: 90     Fields:    Translation:AnimalsCells
    128. Phosphoinositide kinases. Annu Rev Biochem. 1998; 67:481-507. Fruman DA, Meyers RE, Cantley LC. PMID: 9759495.
      View in: PubMed   Mentions: 441     Fields:    Translation:Cells
    129. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science. 1997 Jun 20; 276(5320):1848-50. Chang HW, Aoki M, Fruman D, Auger KR, Bellacosa A, Tsichlis PN, Cantley LC, Roberts TM, Vogt PK. PMID: 9188528.
      View in: PubMed   Mentions: 124     Fields:    Translation:AnimalsCells
    130. Competitive inhibition of calcineurin phosphatase activity by its autoinhibitory domain. Biochem J. 1996 Dec 15; 320 ( Pt 3):879-84. Sagoo JK, Fruman DA, Wesselborg S, Walsh CT, Bierer BE. PMID: 9003375; PMCID: PMC1218010.
      View in: PubMed   Mentions: 16     Fields:    Translation:Cells
    131. Structural organization and alternative splicing of the murine phosphoinositide 3-kinase p85 alpha gene. Genomics. 1996 Oct 01; 37(1):113-21. Fruman DA, Cantley LC, Carpenter CL. PMID: 8921377.
      View in: PubMed   Mentions: 30     Fields:    Translation:AnimalsCells
    132. Identification of a physical interaction between calcineurin and nuclear factor of activated T cells (NFATp). J Biol Chem. 1996 Jan 19; 271(3):1274-7. Wesselborg S, Fruman DA, Sagoo JK, Bierer BE, Burakoff SJ. PMID: 8576111.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    133. Characterization of a mutant calcineurin A alpha gene expressed by EL4 lymphoma cells. Mol Cell Biol. 1995 Jul; 15(7):3857-63. Fruman DA, Pai SY, Burakoff SJ, Bierer BE. PMID: 7791792; PMCID: PMC230625.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    134. The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells. J Immunol. 1995 Feb 15; 154(4):1846-51. Fruman DA, Bierer BE, Benes JE, Burakoff SJ, Austen KF, Katz HR. PMID: 7530743.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    135. FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells. Eur J Immunol. 1995 Feb; 25(2):563-71. Fruman DA, Wood MA, Gjertson CK, Katz HR, Burakoff SJ, Bierer BE. PMID: 7533090.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    136. Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. Blood. 1994 Dec 01; 84(11):3974-9. Pai SY, Fruman DA, Leong T, Neuberg D, Rosano TG, McGarigle C, Antin JH, Bierer BE. PMID: 7949153.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    137. Disruption of T cell development and repertoire selection by calcineurin inhibition in vivo. Transplantation. 1994 Nov 15; 58(9):1037-43. Holländer GA, Fruman DA, Bierer BE, Burakoff SJ. PMID: 7526495.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    138. T cell receptor (beta chain) transgenic mice have selective deficits in gamma delta T cell subpopulations. Transpl Immunol. 1994 Sep; 2(3):218-24. Rimm IJ, Fruman DA, Abhyankar S, Sakamoto H, Orme IM, Milstone D, Seidman JG, Ferrara JL. PMID: 8000850.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    139. Immunophilins in protein folding and immunosuppression. FASEB J. 1994 Apr 01; 8(6):391-400. Fruman DA, Burakoff SJ, Bierer BE. PMID: 7513288.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansAnimalsCells
    140. Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immunol. 1993 Oct; 5(5):763-73. Bierer BE, Holländer G, Fruman D, Burakoff SJ. PMID: 7694595.
      View in: PubMed   Mentions: 25     Fields:    Translation:AnimalsCells
    141. A role for calcineurin in degranulation of murine cytotoxic T lymphocytes. J Immunol. 1993 Apr 01; 150(7):2591-8. Dutz JP, Fruman DA, Burakoff SJ, Bierer BE. PMID: 7681074.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    142. Correlation of calcineurin phosphatase activity and programmed cell death in murine T cell hybridomas. Eur J Immunol. 1992 Oct; 22(10):2513-7. Fruman DA, Mather PE, Burakoff SJ, Bierer BE. PMID: 1382988.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    143. Effects of cyclosporin A and FK506 on Fc epsilon receptor type I-initiated increases in cytokine mRNA in mouse bone marrow-derived progenitor mast cells: resistance to FK506 is associated with a deficiency in FK506-binding protein FKBP12. Proc Natl Acad Sci U S A. 1992 Sep 15; 89(18):8542-6. Kaye RE, Fruman DA, Bierer BE, Albers MW, Zydowsky LD, Ho SI, Jin YJ, Castells MC, Schreiber SL, Walsh CT, et al. PMID: 1382293; PMCID: PMC49956.
      View in: PubMed   Mentions: 18     Fields:    Translation:AnimalsCells
    144. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci U S A. 1992 May 01; 89(9):3686-90. Fruman DA, Klee CB, Bierer BE, Burakoff SJ. PMID: 1373887; PMCID: PMC525555.
      View in: PubMed   Mentions: 178     Fields:    Translation:HumansCells
    145. FK 506 and rapamycin: molecular probes of T-lymphocyte activation. Transplant Proc. 1991 Dec; 23(6):2850-5. Bierer BE, Jin YJ, Fruman DA, Calvo V, Burakoff SJ. PMID: 1721296.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    146. Changes in inositol 1,4,5-trisphosphate mass in agonist-stimulated human neutrophils. Agents Actions. 1991 Sep; 34(1-2):16-9. Fruman DA, Gamache DA, Ernest MJ. PMID: 1665289.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    147. Immunodominance is altered in T cell receptor (beta-chain) transgenic mice without the generation of a hole in the repertoire. J Immunol. 1991 May 01; 146(9):2960-4. Perkins DL, Wang YS, Fruman D, Seidman JG, Rimm IJ. PMID: 1826701.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    David's Networks
    Concepts (610)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (36)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCI Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-4-g3cb31450 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California